Effects on salivary flow rate and composition of withdrawal of and re-exposure to the beta 1-selective antagonist metoprolol in a hypertensive patient population.
Secretion rates and composition of unstimulated and chewing-stimulated whole saliva and 3% citric acid stimulated parotid and submandibular-sublingual secretions were studied in 12 hypertensive patients during withdrawal of and re-exposure to antihypertensive pharmacotherapy. All the patients' blood pressures were well controlled by monotherapy with metoprolol, a beta 1-selective adrenoceptor antagonist. Blood pressure measurements and saliva sampling were performed at about 9:30 a.m., 2 h after intake of breakfast, on days 0 (medicated baseline), 7, 14, 28 (nonmedicated experimental values and nonmedicated baseline) and 35 (medicated experimental values). A significant increase in unstimulated whole saliva secretion rate was observed when metoprolol was withdrawn and a corresponding decrease when the drug was reintroduced. A positive correlation was found between diastolic blood pressure levels and chewing-stimulated whole saliva secretion rates. In unstimulated whole saliva and 3% citric acid stimulated submandibular-sublingual secretion, the output of total protein, amylase, potassium, calcium and phosphate was significantly increased during the withdrawal period and decreased when metoprolol was reintroduced. For chewing-stimulated whole saliva, the corresponding changes were restricted to output of total protein and amylase, while for citric acid stimulated parotid secretion, no changes in salivary composition were observed. Finally, in all secretions one or both of the ratios hexosamine/total protein and sialic acid/total protein were affected, indicating a possible effect of beta-adrenoceptor antagonists on salivary protein synthesis.
Nederfors
T
T
Department of Pharmacology and Clinical Pharmacology, Faculty of Odontology, University of Göteborg, Sweden.
Dahlöf
C
C
D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000681:Amylases / Q000032:analysis; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000032:analysis; D019343:Citric Acid / Q000494:pharmacology; D005260:Female; D005500:Follow-Up Studies; D006595:Hexosamines / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008409:Mastication; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged; D019158:N-Acetylneuraminic Acid / Q000032:analysis; D010306:Parotid Gland / Q000187:drug effects / Q000378:metabolism; D010710:Phosphates / Q000032:analysis; D011188:Potassium / Q000032:analysis; D012463:Saliva / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D012471:Salivary Proteins and Peptides / Q000032:analysis; D012636:Secretory Rate / Q000187:drug effects; D013361:Sublingual Gland / Q000187:drug effects / Q000378:metabolism; D013363:Submandibular Gland / Q000187:drug effects / Q000378:metabolism
D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D006595:Hexosamines; D010710:Phosphates; D012471:Salivary Proteins and Peptides; D019343:Citric Acid; D000681:Amylases; D008790:Metoprolol; D019158:N-Acetylneuraminic Acid; D011188:Potassium; D002118:Calcium